237 related articles for article (PubMed ID: 23331227)
1. Comparison of Bayesian and frequentist meta-analytical approaches for analyzing time to event data.
Bennett MM; Crowe BJ; Price KL; Stamey JD; Seaman JW
J Biopharm Stat; 2013; 23(1):129-45. PubMed ID: 23331227
[TBL] [Abstract][Full Text] [Related]
2. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
3. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
Sweeting MJ; Sutton AJ; Lambert PC
Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
[TBL] [Abstract][Full Text] [Related]
4. Adaptive and repeated cumulative meta-analyses of safety data during a new drug development process.
Quan H; Ma Y; Zheng Y; Cho M; Lorenzato C; Hecquet C
Pharm Stat; 2015; 14(3):161-71. PubMed ID: 25612310
[TBL] [Abstract][Full Text] [Related]
5. Bayesian methodology for the design and interpretation of clinical trials in critical care medicine: a primer for clinicians.
Kalil AC; Sun J
Crit Care Med; 2014 Oct; 42(10):2267-77. PubMed ID: 25226118
[TBL] [Abstract][Full Text] [Related]
6. Multilevel modelling of clustered grouped survival data using Cox regression model: an application to ART dental restorations.
Wong MC; Lam KF; Lo EC
Stat Med; 2006 Feb; 25(3):447-57. PubMed ID: 16143989
[TBL] [Abstract][Full Text] [Related]
7. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of underlying risk as a source of heterogeneity in meta-analyses: a simulation study of Bayesian and frequentist implementations of three models.
Dohoo I; Stryhn H; Sanchez J
Prev Vet Med; 2007 Sep; 81(1-3):38-55. PubMed ID: 17477995
[TBL] [Abstract][Full Text] [Related]
9. An efficient alternative to the stratified Cox model analysis.
Mehrotra DV; Su SC; Li X
Stat Med; 2012 Jul; 31(17):1849-56. PubMed ID: 22437375
[TBL] [Abstract][Full Text] [Related]
10. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
11. Bayesian cure rate frailty models with application to a root canal therapy study.
Yin G
Biometrics; 2005 Jun; 61(2):552-8. PubMed ID: 16011704
[TBL] [Abstract][Full Text] [Related]
12. Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints.
Osman M; Ghosh SK
J Biopharm Stat; 2011 Sep; 21(5):920-37. PubMed ID: 21830923
[TBL] [Abstract][Full Text] [Related]
13. A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data.
Seide SE; Jensen K; Kieser M
Res Synth Methods; 2020 May; 11(3):363-378. PubMed ID: 31955519
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive clinical trials: a dream for statisticians only?
Chevret S
Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
[TBL] [Abstract][Full Text] [Related]
15. Bayesian designs and the control of frequentist characteristics: a practical solution.
Ventz S; Trippa L
Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
[TBL] [Abstract][Full Text] [Related]
16. Shrinkage methods enhanced the accuracy of parameter estimation using Cox models with small number of events.
Lin IF; Chang WP; Liao YN
J Clin Epidemiol; 2013 Jul; 66(7):743-51. PubMed ID: 23566374
[TBL] [Abstract][Full Text] [Related]
17. The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective.
Kruschke JK; Liddell TM
Psychon Bull Rev; 2018 Feb; 25(1):178-206. PubMed ID: 28176294
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis in the design and monitoring of clinical trials.
DerSimonian R
Stat Med; 1996 Jun; 15(12):1237-48; discussion 1249-52. PubMed ID: 8817798
[TBL] [Abstract][Full Text] [Related]
19. Statistical approaches for conducting network meta-analysis in drug development.
Jones B; Roger J; Lane PW; Lawton A; Fletcher C; Cappelleri JC; Tate H; Moneuse P;
Pharm Stat; 2011; 10(6):523-31. PubMed ID: 22213533
[TBL] [Abstract][Full Text] [Related]
20. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
Holzhauer B; Wang C; Schmidli H
Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
